Loading...
•
Mar 26, 2022
Hologic Q2 2022 Earnings Report
Hologic posted strong financial results that significantly exceeded guidance.
Key Takeaways
Hologic's Q2 2022 financial results exceeded expectations, with revenue of $1.436 billion and GAAP diluted EPS of $1.80. The company raised its full-year revenue and EPS guidance, driven by the health and diversity of its base businesses and diagnostic testing for COVID-19.
Revenue of $1.436 billion decreased (6.6%) for the quarter, or (5.2%) in constant currency.
Global diagnostics revenue decreased (7.3%), or (5.6%) in constant currency, primarily driven by lower sales of COVID-19 assays.
Global revenue for the Breast Health division declined (7.7%), or (6.8%) in constant currency, primarily due to semiconductor chip shortages.
Cash flow from operations was exceptionally strong in the second quarter at $1,062.2 million, including tax refunds of $418 million.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Hologic raised its full-year revenue and EPS guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...